EUVIMEDEUVIMED entdecken
Crossref

L26/P-647 Trigger choice for final oocyte maturation does not affect the euploidy rate. A retrospective comparison of dual trigger, human Chorionic Gonadotropin and Gonadotropin-Releasing Hormone Agonist

G. Gaeta, V. Donno, S. Garcia-Martinez, N.P. Polyzos

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.977 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von G. Gaeta und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question Could the final oocyte maturation trigger strategy (human chorionic gonadotropin-hCG vs. gonadotropin-releasing hormone agonist-GnRHa vs. dual trigger) affect the euploidy rate? Summary answer No significant differences in euploidy rates were observed according to the final oocyte maturation trigger, whether hCG, GnRHa, or a dual trigger was used. What is known already Final oocyte maturation is a key step in IVF(in vitro fertilization) and has traditionally been triggered with hCG. The adoption of GnRH-antagonist protocols has enabled the use of GnRH-agonist triggers, while dual-trigger strategies combining GnRH-agonist and hCG are increasingly applied across different responder profiles. Although these approaches are widely used and associated with comparable reproductive outcomes, evidence on their impact on embryo euploidy remains limited. Few studies have reported similar euploidy rates between dual trigger and hCG alone, and comparisons between GnRH agonist and dual trigger are lacking. Study design, size, duration A retrospective single-centre study was conducted at a university-affiliated fertility centre, including IVF cycles with preimplantation genetic testing for aneuploidy (PGT-A) performed between January 2021 and December 2024. Cycles were compared according to the oocyte-trigger strategy: hCG (r-hCG 250µg or u-hCG 5,000IU), GnRH agonist (triptorelin 0.2 mg), or dual trigger (triptorelin 0.2 mg + r-hCG 250µg or u-hCG 5,000IU). Cycles with abnormal maternal or paternal karyotypes were excluded. Participants/materials, setting, methods A total of 2,677 IVF–PGT-A cycles were analyzed. Embryonic euploidy rates were compared among three trigger strategies (hCG vs. GnRH-a vs. dual trigger) and stratified by female age (<35, 35–37, 38–40, 41–42, >42 years). Descriptive statistics and ANOVA were used for bivariate analyses. Euploidy rates were estimated using a multivariable mixed-effects Poisson regression adjusted for clinical covariates, and results were reported as incidence rate ratios (IRR) with 95% confidence intervals. Main results and the role of chance Overall, a total of 2677 cycles were included: 728 with GnRH-agonist trigger; 1747 with dual-trigger, and 202 with hCG alone. Patients receiving a GnRH-agonist trigger were younger than those receiving dual or hCG-trigger (39.4±3.1vs.40.6±2.7vs.40.7±2.6 years; P<0.001), with higher AMH levels (2.9±2.2vs.1.3±1.2vs.1.4±1.3 ng/mL; P<0.001), while BMI did not differ (24.6±5.1vs.24.2±4.5vs.23.6±5.1 kg/m²; P=0.307). Regarding the stimulation outcomes, according to the higher ovarian reserve, the GnRH-agonist group showed higher number of oocytes retrieved as compared to the dual and hCG alone, respectively (13.7±7.5vs.7.8±4.8vs.7.4±5.1;p< 0.001), as well as higher number of MII oocytes (9.8±5.5vs.5.9±3.7vs.5.2±3.8, p < 0.001), fertilized oocytes (7.5±4.6vs.4.5±3.1vs.3.6±3.1; p < 0.001), and number of blastocysts (3.2±2.7vs.1.8±1.8vs.1.4±1.6 p<0.001), despite lower total gonadotropin doses (2449.6±868.7vs.2745.8±988.0vs.2856.2±1032.0 IU; p < 0.001). A total of 5758 blastocysts were biopsied. Embryonic euploidy rates did not differ among trigger strategies. The overall euploidy rate was (37%[95%CI:36%–39%]) and was comparable across groups: 39%[95%CI:37%-41%] in the GnRH-agonist, (36%[95% CI:34%–38%]) in the dual-trigger, and (34%[95%CI:29%–40%]) in the hCG. These findings were confirmed in a multivariable mixed-effects Poisson regression analysis adjusted for female age, BMI, total gonadotropin dose, and days of stimulation, showing no difference in euploidy rates for GnRH-agonist vs dual trigger [IRRs:1.03 (95%CI:0.88–1.21)] or GnRH-agonist vs hCG [IRRs: 0.76 (95%CI:0.51–1.15)]. Limitations, reasons for caution The main limitation of this study is its retrospective design. Despite the sample size and the use of multivariable regression models to account for confounding factors, the presence of residual bias cannot be excluded. Wider implications of the findings Findings from the current study confirm previous evidence, suggesting no impact of trigger strategy on euploidy rates when dual trigger, human chorionic gonadotropin, or gonadotropin-releasing hormone agonist alone are used. Therefore, trigger choice can be individualized according to patient profile and ovarian response during stimulation, without concern for embryo euploidy. Trial registration number No

Zitieren

APA

Gaeta, G., Donno, V., Garcia-Martinez, S., & Polyzos, N. (2026). L26/P-647 Trigger choice for final oocyte maturation does not affect the euploidy rate. A retrospective comparison of dual trigger, human Chorionic Gonadotropin and Gonadotropin-Releasing Hormone Agonist. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.977

Vancouver

Gaeta G, Donno V, Garcia-Martinez S, Polyzos N. L26/P-647 Trigger choice for final oocyte maturation does not affect the euploidy rate. A retrospective comparison of dual trigger, human Chorionic Gonadotropin and Gonadotropin-Releasing Hormone Agonist. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.977

BibTeX
@article{Gaeta2026,
  author = {Gaeta, G. and Donno, V. and Garcia-Martinez, S. and Polyzos, N.P.},
  title = {L26/P-647 Trigger choice for final oocyte maturation does not affect the euploidy rate. A retrospective comparison of dual trigger, human Chorionic Gonadotropin and Gonadotropin-Releasing Hormone Agonist},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.977}
}
Kostenlos starten →